"Novobiocin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189)
| Descriptor ID |
D009675
|
| MeSH Number(s) |
D03.383.663.283.446.139.500 D03.633.100.150.446.139.500 D09.408.554
|
| Concept/Terms |
Novobiocin- Novobiocin
- Streptonivicin
- Crystallinic Acid
Novobiocin Sodium- Novobiocin Sodium
- Sodium, Novobiocin
- Novobiocin, Monosodium Salt
- Monosodium Salt Novobiocin
|
Below are MeSH descriptors whose meaning is more general than "Novobiocin".
Below are MeSH descriptors whose meaning is more specific than "Novobiocin".
This graph shows the total number of publications written about "Novobiocin" by people in this website by year, and whether "Novobiocin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 2 | 3 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Novobiocin" by people in Profiles.
-
Identification and Structure-Activity Relationships of Novel Compounds that Potentiate the Activities of Antibiotics in Escherichia coli. J Med Chem. 2017 07 27; 60(14):6205-6219.
-
Novobiocin Susceptibility of MukBEF-Deficient Escherichia coli Is Combinatorial with Efflux and Resides in DNA Topoisomerases. Antimicrob Agents Chemother. 2016 05; 60(5):2949-53.
-
Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol. 2013 Oct; 11(8):478-88.
-
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer. 2011 Oct 31; 11:468.
-
Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg Med Chem Lett. 2011 Dec 01; 21(23):7170-4.
-
Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol. 2011 Aug 19; 6(8):800-7.
-
A systematic protocol for the characterization of Hsp90 modulators. Bioorg Med Chem. 2011 Jan 01; 19(1):684-92.
-
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. Antimicrob Agents Chemother. 2010 Dec; 54(12):5366-8.
-
Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate. 2010 Jan 01; 70(1):27-36.
-
KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol. 2009 Dec; 76(6):1314-22.